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SUMMARY 
Background: Electroconvulsive therapy is frequently considered when pharmacotherapy is ineffective. In such cases the 
combination of the two treatment modalities are commonly used. Amisulpiride, a second generation antipsychotic drug is used in the 
treatment of schizophrenia and psychotic depression. When amisulpiride is ineffective as a monotherapy, combination with ECT 
could be an option to enhance its efficacy. To the best of our knowledge, to date there have been no data about the safety of this 
combination. 
Subjects and methods: Medical notes of all patients who were given ECT while on amisulpiride were selected from the archives 
of the Department of Psychiatry, Semmelweis University Medical School, Budapest, covering a 10-year period. A randomly selected 
matched control group was formed from patients who underwent ECT but were not taking amisulpiride. Patients in both groups also 
received a variety of psychotropic drugs other than amisulpide. Side effects were compared between the two groups of patients. 
Results: Twenty patients received amisulpride with ECT. The most common side effects were headache, hypertension, 
tachycardia, nausea, dizziness, confusion, psychomotor agitation, sialorrhea, and prolonged seizure activity. All adverse effects 
resolved within 24 hours. No side effects of any kind were observed in 7 and 8 cases in the study and control groups, respectively.  
Conclusions: This was the first study that examined the safety of amisulpride-ECT combination in schizophrenia. Comparing the 
side-effects between the study and control groups, no significant differences were detected in terms of their types or frequency. The 
amisulpiride-ECT combination appears to be a safe treatment option. 
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INTRODUCTION 
The main indications of electroconvulsive therapy 
(ECT) are affective disorders (mainly depression) and 
certain clinical features of schizophrenia (Gazdag et al. 
2009a, Zervas et al. 2011, Moksnes & Ilner 2010, 
Gazdag et al. 2009b). ECT as monotherapy has been 
effective in the treatment of major depression (Bailine et 
al. 2010) and is recommended by most influential 
guidelines (American Psychiatric Association 2001, 
Royal College of Psychiatrists 2005) although in clini-
cal practice combination of ECT with pharmacotherapy 
is quite common (Ravanić et al. 2009).  
In all international recommendations published in 
the last ten years, second generation antipsychotics 
(SGA) are considered as first-line treatment in psychotic 
disorders, mainly due to their favorable safety profile 
(American Psychiatric Association 2004). Amisulpiride, 
a substituted benzamide, is a SGA with unique pharma-
cological properties and therapeutic profile. Due to its 
effect of "dual dopamine blockade", amisulpiride acts as 
an antipsychotic at high doses while it has a dis-
inhibitory action at low doses which explains its 
effectiveness in both positive and negative symptoms of 
schizophrenia and as well as in depression (Wetzel el al. 
1998, Danion et al. 1999, Smeraldi 1998, Lecrubier et 
al. 1998). Most common side effects of amisulpride 
include sleep disturbance, anxiety, agitation (5-10%), 
drowsiness, constipation, nausea; vomiting and dry 
mouth (2%) can also appear (Green 2002). Prolongation 
of the QTc interval (Stöllberger et al. 2005) and 
bradycardia (Pedrosa et al. 2001) could also occur with 
amisulpride, but these are rather rare.  
The largest study reporting on the combined treat-
ment of ECT and different classes of antipsychotic drugs 
included 455 patients (Nothdurfter et al. 2006). No 
difference in clinical efficacy was found between ECT 
monotherapy and the ECT-first generation antipsychotic 
(FGA) combinations. Furthermore, no clinically mean-
ingful differences in side effects were found between 
ECT monotherapy and ECT-FGA or ECT-SGA com-
binations (Nothdurfter et al. 2006). As for the epilepto-
genic properties of the SGAs, olanzapine and clozapine 
lower seizure threshold, whereas quetiapine could 
increase it (Gazdag et al. 2004). A higher risk is 
associated with the clozapine-ECT combination in terms 
of development of spontaneous seizures (Pisani et al. 
2002) and prolongation of seizure activity (Bloch et al. 
1996, Masiar & Johns 1991), although the latter could 
be clinically insignificant (Cardwell & Nakai 1995).  
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In a sample of 15 patients with treatment-resistant 
schizophrenia, no adverse effects were observed with 
ECT-olanzapine or ECT-risperidone combinations; in 
only one case was asymptomatic ST elevation detected 
in the V3, V4 ECG leads after the second ECT session 
(Tang & Ungvari 2002). A few case reports attest to the 
safe administration of ECT together with ziprasidone 
(Masdrakis et al. 2010) or aripiprazol (Masdrakis et al. 
2008).  
To the best of our knowledge, there are no data 
about the safety of the ECT and amisulpride combi-
nation. Thus, the aim of this study was to assess the 
safety of this treatment option. 
 
SUBJECTS AND METHODS 
This was a chart review of patients who received 
ECT at the Department of Psychiatry and Psycho-
therapy, Semmelweis University, Budapest, between 
2000 and 2010. The medical notes of patients who were 
given ECT while on amisulpiride – singly or in 
combination with other psychotropic drugs – were 
selected and analyzed. As amisulpride can only be used 
in the treatment of schizophrenia in Hungary, all 
patients had a diagnosis of schizophrenia which was 
established according to ICD-10 criteria. A randomly 
selected control group matched according to age, sex 
and diagnosis was formed comprising patients who 
underwent ECT at the same Department during the 
study period but did not receive amisulpiride. Side 
effects and adverse events during the course of ECT that 
appeared in association with the combined treatment 
were analyzed and compared between the two groups.  
The statistical analysis was performed with the SPSS 
11.5 Package (Statistical Package for Social Sciences, 
Chicago, IL, USA). Descriptive data are presented with 
means, confidence intervals and standard deviations. If 
the distribution of the variables was normal, data were 
compared with t-tests; in case of non-normal 
distribution (dose of clonazepam, number of sessions, 
number of restimulations) with Mann-Whitney U-tests. 
The practice of consenting to ECT in Hungary 
conforms to international standards (Gazdag et al. in 
press).  
 
RESULTS 
Before commencing the course of ECT, all patients 
received pharmacotherapy in adequate doses and for 
adequate length without noticeable improvement. ECT 
was administered with a Thymatron DGx device 
delivering constant-current, brief-pulse, bi-directional 
square-wave impulses with bilateral frontotemporal 
electrode placement for all patients. After premedication 
with atropine (0.5 mg iv.), propofol (1 mg/kg) and 
succinylcholine (0.5–1 mg/kg) were used for sleep 
induction and muscle relaxation, respectively. Seizure 
activity was monitored with EEG and EMG.  
Over the 10-year period, 222 patients were treated 
with ECT; in 182 cases (82%) ECT was administered in 
combination with antipsychotic drugs. Twenty patients 
received amisulpride with ECT. The mean age of the 
study and control groups was 43.2+15.1 and 43.3+15.2 
years, respectively; 10 patients (50%) were female in 
each group. The mean daily dose of amisulpiride was 
745±258 mg (range: 200 -1200 mg). The mean daily 
dose of the most commonly used sedative drug, 
clonazepam was 2.8+1.6 mg (range: 2-6 mg) and 
2.0+0.0 mg in the study and control groups, respectively 
(p=0.30). Additional psychotropic drugs taken in the 
study group included clozapine (13 cases), clonazepam 
(6 cases), haloperidol and lithium 5 cases each, lamo-
trigine and alprazolam 2 cases each, and quetiapine, 
cisordinol, olanzapine, citalopram, sertraline, mirta-
zapine, paroxetine, reboxetine, sodium valproate and 
biperiden, 1 case each. In the control group the number 
of concomitant medications was clonazepam (12 cases), 
clozapine (8 cases), haloperidol (7 cases), lithium (6 
cases), risperidone, sodium valproate and quetiapine 3 
cases each, olanzapine, zuclopenthixol, alprazolam, 
bupropione, paroxetine, lamotrigine, mirtazapine and 
biperiden 1 case each. 
ECT was administered twice a week. There was no 
significant difference regarding the number of sessions 
(p=0.41), number of repeated stimulations (p=0.36), 
seizure threshold (p=0.24), and the mean seizure 
duration measured with EEG (p=0.19) and EMG 
(p=0.07) between the two groups. The mean stimulus 
doses in the study and control groups were 140.5 mC 
(CI: 54.6–204.9, SD: 43.5) and 159.9 mC (CI: 75.6– 
352.8, SD: 58.4), respectively. Seizure threshold was 
determined with dose titration.  
 
Table 1. Frequency of the side-effects in the study and 
control groups 
Side–effects Amisulpiride-
ECT group 
Control 
group 
Headache 5 2 
Hypertension 4 6 
Tachycardia 1 4 
Nausea 1 0 
Dizziness 0 1 
Confusion 2 1 
Psychomotor agitation 1 2 
Seizure prolongation 1 1 
Sialorrhea 1 0 
 
The most common side effects were headache, 
hypertension, tachycardia, nausea, dizziness, confusion, 
psychomotor agitation, sialorrhea, and prolonged 
seizure activity (Table 1). All were resolved within 24 
hours. The number of side-effects is shown in Table 1. 
No side effects of any kind were observed in 7 and 8 
cases in the study and control groups, respectively. No 
ECT course was interrupted or shortened because of 
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side effects. In the study group metamizole-Na was 
given for headache in 5 cases. In one case 1 mg of 
clonazepam was administered intravenously for 
prolonged seizure activity; the rest of the side effects 
were spontaneously resolved. In the control group 
metamizole-Na was given for headache in 2 cases and 
25 mg of metoprolol for tachycardia on one occasion.  
 
DISCUSSION 
The concomitant use of ECT and antipsychotic 
drugs raises the important questions of effectiveness and 
side effects. The majority of studies reported that the 
combined treatment was safe and effective although 
methodological shortcomings render this conclusion 
preliminary (Braga & Petrides 2005). 
To the best of our knowledge, this was the first study 
that examined the safety of amisulpride-ECT combi-
nation. This treatment combination was well–tolerated 
in all 20 cases. Side-effects occurring during the combi-
ned ECT-amisulpiride treatment were transient and 
mild. Comparing the side-effects between the study and 
control groups, no significant differences were detected 
in terms of their types or frequency. The amisulpiride-
ECT combination did not cause more or more severe 
side-effects even in high amisulpiride doses. Cardiac 
and central nervous system side-effects should be paid 
particular attention (Sartorius et al. 2005) as they could 
appear more frequently with increasing age and could 
be more important in a larger sample. 
The main limitations of this study include the 
retrospective design the relatively low number of cases, 
the concomitant treatment with other drugs, the 
relatively young age of patients and the lack of ECG 
monitoring.  
 
CONCLUSION 
In conclusion, the amisulpride–ECT combination is 
safe; more accurately, adding amisulpride to other 
psychotropic drugs while administering ECT is safe in 
clinical practice.  
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